Estimating and Disclosing the Risk of Developing Alzheimer's Disease: Challenges, Controversies and Future Directions

Overview

Journal Future Neurol

Specialty Neurology

Date 2010 Sep 22

PMID 20856693

Citations 14

Authors

J Scott Roberts

Sarah M Tersegno

Affiliations

Soon will be listed here.

Abstract

With Alzheimer's disease increasing in prevalence and public awareness, more people are becoming interested in learning their chances of developing this condition. Disclosing Alzheimer's disease risk has been discouraged because of the limited predictive value of available tests, lack of prevention and treatment options, and concerns regarding potential psychological and social harms. However, challenges to this status quo include the availability of direct-to-consumer health risk information (e.g., genetic susceptibility tests), as well as a growing literature suggesting that people seeking risk information for Alzheimer's disease through formal education and counseling protocols generally find it useful and do not experience adverse effects. This paper reviews current and potential methods of risk assessment for Alzheimer's disease, discusses the process and impact of disclosing risk to interested patients and consumers, and considers the practical and ethical challenges in this emerging area. Anticipated future directions are addressed.

Citing Articles

Normal-But-Low Serum Folate Levels and the Risks for Cognitive Impairment.

Jang S, Han J, Shin J, Kim T, Kwak K, Kim K Psychiatry Investig. 2019; 16(7):532-538.

PMID: 31352735 PMC: 6664218. DOI: 10.30773/pi.2019.05.29.

A mixed-methods study of cultural beliefs about dementia and genetic testing among Mexicans and Mexican-Americans at-risk for autosomal dominant Alzheimer's disease.

Withers M, Sayegh P, Rodriguez-Agudelo Y, Ernstrom K, Raman R, Montoya L J Genet Couns. 2019; 28(5):921-932.

PMID: 31207006 PMC: 7500864. DOI: 10.1002/jgc4.1133.

Personalized risk for clinical progression in cognitively normal subjects-the ABIDE project.

van Maurik I, Slot R, Verfaillie S, Zwan M, Bouwman F, Prins N Alzheimers Res Ther. 2019; 11(1):33.

PMID: 30987684 PMC: 6466790. DOI: 10.1186/s13195-019-0487-y.

From information to follow-up: Ethical recommendations to facilitate the disclosure of amyloid PET scan results in a research setting.

Vanderschaeghe G, Schaeverbeke J, Bruffaerts R, Vandenberghe R, Dierickx K Alzheimers Dement (N Y). 2018; 4:243-251.

PMID: 29955667 PMC: 6021550. DOI: 10.1016/j.trci.2018.04.002.

Perspectives on Communicating Biomarker-Based Assessments of Alzheimer's Disease to Cognitively Healthy Individuals.

Milne R, Bunnik E, Diaz A, Richard E, Badger S, Gove D J Alzheimers Dis. 2018; 62(2):487-498.

PMID: 29480179 PMC: 5836405. DOI: 10.3233/JAD-170813.

References

Ashida S, Koehly L, Roberts J, Chen C, Hiraki S, Green R . Disclosing the disclosure: factors associated with communicating the results of genetic susceptibility testing for Alzheimer's disease. J Health Commun. 2009; 14(8):768-84. PMC: 2801901. DOI: 10.1080/10810730903295518. View

Korobkin R, Rajkumar R . The Genetic Information Nondiscrimination Act--a half-step toward risk sharing. N Engl J Med. 2008; 359(4):335-7. DOI: 10.1056/NEJMp0804352. View

Offit K . Genomic profiles for disease risk: predictive or premature?. JAMA. 2008; 299(11):1353-5. DOI: 10.1001/jama.299.11.1353. View

Huggins M, Bloch M, Wiggins S, Adam S, Suchowersky O, Trew M . Predictive testing for Huntington disease in Canada: adverse effects and unexpected results in those receiving a decreased risk. Am J Med Genet. 1992; 42(4):508-15. DOI: 10.1002/ajmg.1320420417. View

Lipkus I . Numeric, verbal, and visual formats of conveying health risks: suggested best practices and future recommendations. Med Decis Making. 2007; 27(5):696-713. DOI: 10.1177/0272989X07307271. View

Roberts J, LaRusse S, Katzen H, Whitehouse P, Barber M, Post S . Reasons for seeking genetic susceptibility testing among first-degree relatives of people with Alzheimer disease. Alzheimer Dis Assoc Disord. 2003; 17(2):86-93. DOI: 10.1097/00002093-200304000-00006. View

Green M, Peterson S, Baker M, Harper G, Friedman L, Rubinstein W . Effect of a computer-based decision aid on knowledge, perceptions, and intentions about genetic testing for breast cancer susceptibility: a randomized controlled trial. JAMA. 2004; 292(4):442-52. PMC: 1237120. DOI: 10.1001/jama.292.4.442. View

Stern Y, Gurland B, Tatemichi T, Tang M, Wilder D, Mayeux R . Influence of education and occupation on the incidence of Alzheimer's disease. JAMA. 1994; 271(13):1004-10. View

Almqvist E, Bloch M, Brinkman R, Craufurd D, Hayden M . A worldwide assessment of the frequency of suicide, suicide attempts, or psychiatric hospitalization after predictive testing for Huntington disease. Am J Hum Genet. 1999; 64(5):1293-304. PMC: 1377865. DOI: 10.1086/302374. View

10.

Petersen R, Thomas R, Grundman M, Bennett D, Doody R, Ferris S . Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005; 352(23):2379-88. DOI: 10.1056/NEJMoa050151. View

11.

Hampel H, Burger K, Teipel S, Bokde A, Zetterberg H, Blennow K . Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement. 2008; 4(1):38-48. DOI: 10.1016/j.jalz.2007.08.006. View

12.

Cupples L, Farrer L, Sadovnick A, Relkin N, Whitehouse P, Green R . Estimating risk curves for first-degree relatives of patients with Alzheimer's disease: the REVEAL study. Genet Med. 2004; 6(4):192-6. DOI: 10.1097/01.gim.0000132679.92238.58. View

13.

Phelan J, Yang L, Cruz-Rojas R . Effects of attributing serious mental illnesses to genetic causes on orientations to treatment. Psychiatr Serv. 2006; 57(3):382-7. DOI: 10.1176/appi.ps.57.3.382. View

14.

Meyer M, Tschanz J, Norton M, Welsh-Bohmer K, Steffens D, Wyse B . APOE genotype predicts when--not whether--one is predisposed to develop Alzheimer disease. Nat Genet. 1998; 19(4):321-2. DOI: 10.1038/1206. View

15.

Christensen K, Roberts J, Royal C, Fasaye G, Obisesan T, Cupples L . Incorporating ethnicity into genetic risk assessment for Alzheimer disease: the REVEAL study experience. Genet Med. 2008; 10(3):207-14. PMC: 2483343. DOI: 10.1097/GIM.0b013e318164e4cf. View

16.

Guttmacher A, Jenkins J, Uhlmann W . Genomic medicine: who will practice it? A call to open arms. Am J Med Genet. 2002; 106(3):216-22. DOI: 10.1002/ajmg.10008. View

17.

Ward M . Biomarkers for Alzheimer's disease. Expert Rev Mol Diagn. 2007; 7(5):635-46. DOI: 10.1586/14737159.7.5.635. View

18.

Chao S, Roberts J, Marteau T, Silliman R, Cupples L, Green R . Health behavior changes after genetic risk assessment for Alzheimer disease: The REVEAL Study. Alzheimer Dis Assoc Disord. 2008; 22(1):94-7. PMC: 2483341. DOI: 10.1097/WAD.0b013e31815a9dcc. View

19.

Heyn P, Abreu B, Ottenbacher K . The effects of exercise training on elderly persons with cognitive impairment and dementia: a meta-analysis. Arch Phys Med Rehabil. 2004; 85(10):1694-704. DOI: 10.1016/j.apmr.2004.03.019. View

20.

Gail M, Brinton L, Byar D, Corle D, Green S, Schairer C . Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989; 81(24):1879-86. DOI: 10.1093/jnci/81.24.1879. View